On Monday, Sage Therapeutics Inc (NASDAQ: SAGE) was 6.62% up from the session before settling in for the closing price of $8.01. A 52-week range for SAGE has been $5.84 – $28.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 3395.58% over the last five years. When this article was written, the company’s average yearly earnings per share was at 28.69%. With a float of $50.28 million, this company’s outstanding shares have now reached $60.04 million.
The firm has a total of 487 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.47%, operating margin of -495.97%, and the pretax margin is -458.3%.
Sage Therapeutics Inc (SAGE) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Sage Therapeutics Inc stocks. The insider ownership of Sage Therapeutics Inc is 17.64%, while institutional ownership is 89.11%.
Sage Therapeutics Inc (SAGE) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -3.37 earnings per share (EPS) during the time that was less than consensus figure (set at -2.73) by -0.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.80% during the next five years compared to -2.28% drop over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
You can see what Sage Therapeutics Inc (SAGE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.41, a number that is poised to hit -1.54 in the next quarter and is forecasted to reach -4.53 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Analysing the last 5-days average volume posted by the [Sage Therapeutics Inc, SAGE], we can find that recorded value of 0.68 million was lower than the volume posted last year of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 93.17%. Additionally, its Average True Range was 0.43.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 35.39%, which indicates a significant decrease from 96.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.39% in the past 14 days, which was lower than the 65.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.53, while its 200-day Moving Average is $13.77. Now, the first resistance to watch is $8.74. This is followed by the second major resistance level at $8.94. The third major resistance level sits at $9.26. If the price goes on to break the first support level at $8.22, it is likely to go to the next support level at $7.90. Should the price break the second support level, the third support level stands at $7.70.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
There are 60,182K outstanding shares of the company, which has a market capitalization of 521.37 million. As of now, sales total 86,460 K while income totals -541,490 K. Its latest quarter income was 8,650 K while its last quarter net income were -102,850 K.
